Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
B6E
vs
DAX Index
B6E
Over the past 12 months, B6E has significantly outperformed DAX Index, delivering a return of +35% compared to DAX Index's +7% growth.
Stocks Performance
B6E vs DAX Index
Performance Gap
B6E vs DAX Index
Create a free account · No card needed
Performance By Year
B6E vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Swedish Orphan Biovitrum AB (publ)
Glance View
Swedish Orphan Biovitrum, usually called Sobi, is a biopharmaceutical company that develops and sells medicines for rare diseases. Its main focus is on blood disorders, immune-related conditions, and other specialist therapies that treat patients with serious illnesses that are often hard to manage with standard drugs. Sobi makes money by selling prescription medicines to hospitals, specialty pharmacies, and healthcare systems, often through long-term treatment relationships. Its products include therapies used in hemophilia and other rare blood diseases, as well as medicines for certain immune and inflammatory conditions. The company also works with partners to develop and commercialize some of its treatments, which can add licensing and collaboration income. What makes Sobi different is its focus on a narrow set of rare diseases where patients need highly targeted, specialized care. Instead of selling a broad mix of mass-market drugs, it concentrates on treatments that are used by smaller patient groups but require deep medical expertise, strong relationships with specialists, and reliable supply.
Create a free account · No card needed